Journal article icon

Journal article

First 20 years with recombinant FVIIa (NovoSeven).

Abstract:

This review describes the background for the development of recombinant FVIIa (rFVIIa; NovoSeven) for use in haemophilic patients with inhibitors. The first proof of principle for using pharmacological doses of FVIIa as a haemostatic agent was obtained by producing small amounts of pure plasma-derived FVIIa, which showed encouraging effect in two patients with haemophilia A and inhibitors. To make pure FVIIa available for use in a larger number of patients, rFVIIa was produced that was approv...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Journal:
Haemophilia : the official journal of the World Federation of Hemophilia
Volume:
17
Issue:
1
Pages:
e172-e182
Publication date:
2011-01-05
DOI:
EISSN:
1365-2516
ISSN:
1351-8216
URN:
uuid:afe16ef3-c776-4350-8d58-6d4f986dd23a
Source identifiers:
219796
Local pid:
pubs:219796

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP